Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 16, 2017
Clinical development programs advancing toward key milestonesDr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNPNovel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and ALECT2...
Nov 7, 2017
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1 million, provides funding to advance diverse pipelinePresented new research at HFSA Annual Scientific Meet...
Nov 1, 2017
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Cre...
Oct 31, 2017
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine months of 2017 on November 7,...
Sep 28, 2017
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) studyObserved clinical efficacy...
Sep 18, 2017
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP ProductionClinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of LifeData Presented at Heart Failure Society of...
Aug 15, 2017
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Irelan...
Aug 8, 2017
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipelineInitiated, with Roche, the global Phase 2 PASADENA st...
Aug 1, 2017
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six months of 2017 on August 8, 2...
Jul 5, 2017
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's diseaseProthena to receive $30 million milestone payment under collaboration agreement with Roche DUBLIN, Ireland, July 05, 2017 (GLOBE...
Jun 12, 2017
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD, as Chief Scientific Officer (CSO). Dr. Zago, wh...
May 16, 2017
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. Dr. Noonberg ...
May 9, 2017
Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million raised through March 2017 public equity offering, provides funding to advance R&D pipelineCompleted enro...
May 2, 2017
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial ...
Apr 26, 2017
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Deutsche Bank 42nd...
Page:
...
Next Last
 
= add release to Briefcase